Last 48 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
CONMED Corporation's quarterly P/E stands at 19.6x, down 75.3% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 63.2% YoY to 10.3x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 25.22 | 19.64 | 18.80 | 127.66 | 18.87 | 79.46 | 15.84 | 11.45 | 18.05 | 31.78 | 26.07 | 50.42 | 79.01 |
| — | -75.3% | +18.6% | +1014.7% | +4.5% | +150.1% | -39.2% | -77.3% | -77.2% | -92.9% | +1.2% | +272.4% | — | |
| P/S Ratio | 0.85 | 0.85 | 0.84 | 1.08 | 1.18 | 1.47 | 1.54 | 1.77 | 1.62 | 2.00 | 2.64 | 2.62 | 3.40 |
| — | -42.0% | -45.2% | -39.0% | -27.4% | -26.6% | -41.6% | -32.7% | -52.3% | -26.9% | -3.5% | +15.8% | +32.2% | |
| P/B Ratio | 1.15 | 1.06 | 1.22 | 1.45 | 1.61 | 1.92 | 2.21 | 2.40 | 2.45 | 2.93 | 4.14 | 4.01 | 5.54 |
| — | -44.7% | -44.9% | -39.6% | -34.0% | -34.3% | -46.5% | -40.2% | -55.8% | -32.0% | +12.5% | +15.3% | +30.7% | |
| P/FCF | 7.78 | 25.59 | 7.64 | 7.53 | 17.28 | 12.46 | 13.55 | 11.71 | 13.57 | 23.11 | 16.73 | 19.61 | 48.78 |
| — | +105.4% | -43.6% | -35.7% | +27.3% | -46.1% | -19.0% | -40.3% | -72.2% | — | — | -39.6% | -10.8% | |
| EV / EBITDA | 10.17 | 10.31 | 5.99 | 17.51 | 11.23 | 28.04 | 10.68 | 9.38 | 11.91 | 16.31 | 16.13 | 24.33 | 33.02 |
| — | -63.2% | -43.9% | +86.7% | -5.7% | +71.9% | -33.8% | -61.4% | -63.9% | -53.3% | -71.5% | +16.6% | +28.3% | |
| EV / EBIT | 13.95 | 17.40 | 7.68 | 29.32 | 14.77 | 59.63 | 14.34 | 11.95 | 16.42 | 24.71 | 21.91 | 34.47 | 48.63 |
| — | -70.8% | -46.4% | +145.4% | -10.0% | +141.3% | -34.6% | -65.3% | -66.2% | -70.7% | — | -4.4% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
CONMED Corporation's operating margin was 8.7% in Q1 2026, down 9.3 pp QoQ and up 5.1 pp YoY. The trailing four-quarter average of 11.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 10.1% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8% | 57.9% | 57.1% | 46.7% | 52.6% | 52.6% | 57.3% | 56.5% | 55.3% | 55.1% | 55.7% | 55.2% | 53.7% |
| — | +10.1% | -0.4% | -17.5% | -4.9% | -4.6% | +2.9% | +2.4% | +3.0% | +4.8% | +6.0% | +0.1% | -1.9% | |
| Operating Margin | 10.3% | 8.7% | 17.9% | 5.7% | 12.2% | 3.6% | 15.2% | 20.7% | 14.2% | 11.2% | 15.3% | 9.9% | 8.6% |
| — | +140.7% | +18.0% | -72.4% | -14.3% | -67.9% | -1.1% | +108.6% | +64.3% | +160.9% | +3615.6% | +12.9% | -2.2% | |
| Net Margin | 3.4% | 4.4% | 4.5% | 0.8% | 6.2% | 1.9% | 9.8% | 15.5% | 9.0% | 6.3% | 10.1% | 5.2% | 4.3% |
| — | +130.8% | -54.1% | -94.5% | -30.8% | -70.1% | -3.5% | +197.5% | +108.8% | +925.3% | -4.6% | -69.0% | +107.1% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.7% | 1.3% | 1.6% | 0.3% | 2.2% | 0.6% | 3.6% | 5.4% | 3.5% | 2.3% | 4.1% | 2.0% | 1.8% |
| — | +116.7% | -54.0% | -94.7% | -37.3% | -73.3% | -12.2% | +168.7% | +92.7% | +860.9% | +11.5% | -69.8% | +107.8% | |
| ROA | 2.0% | 0.6% | 0.7% | 0.1% | 0.9% | 0.3% | 1.5% | 2.1% | 1.3% | 0.9% | 1.4% | 0.7% | 0.6% |
| — | +127.3% | -50.7% | -94.2% | -29.0% | -69.3% | +2.1% | +212.5% | +120.6% | +985.3% | +23.4% | -67.8% | +106.8% | |
| ROIC | 5.8% | 1.1% | 2.7% | 0.8% | 1.7% | 0.5% | 2.1% | 2.7% | 1.9% | 1.5% | 2.1% | 1.3% | 1.1% |
| — | +139.4% | +28.4% | -70.6% | -12.7% | -68.0% | +1.3% | +112.0% | +69.6% | +173.2% | +4596.4% | +16.2% | -3.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
CONMED Corporation's Debt/EBITDA ratio is 18.6x, up from 9.7x last quarter — elevated, raising questions about debt serviceability.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.81 | 0.85 | 0.81 | 0.85 | 0.88 | 0.91 | 0.94 | 1.01 | 1.10 | 1.16 | 1.17 | 1.27 | 1.33 |
| — | -7.3% | -14.1% | -16.0% | -19.7% | -21.3% | -19.4% | -20.7% | -17.9% | -18.1% | -17.5% | -12.1% | -8.6% | |
| Debt / EBITDA | 4.32 | 18.61 | 9.74 | 26.29 | 16.07 | 36.54 | 12.85 | 11.24 | 14.87 | 18.68 | 14.28 | 23.59 | 25.78 |
| — | -49.1% | -24.2% | +133.8% | +8.0% | +95.7% | -10.0% | -52.3% | -42.3% | -46.3% | -77.5% | -4.7% | -3.7% | |
| Current Ratio | 2.14 | 2.29 | 2.14 | 2.10 | 2.23 | 2.26 | 2.30 | 2.27 | 2.34 | 2.18 | 1.98 | 1.66 | 1.74 |
| — | +1.5% | -7.2% | -7.3% | -4.7% | +3.4% | +16.1% | +36.6% | +34.4% | +14.7% | +1.1% | -39.6% | -39.3% | |
| Quick Ratio | 1.01 | 2.29 | 2.14 | 0.95 | 1.00 | 1.00 | 1.05 | 1.06 | 1.13 | 1.08 | 0.96 | 0.80 | 0.82 |
| — | +128.1% | +102.5% | -10.5% | -11.4% | -6.6% | +10.2% | +32.7% | +38.7% | +25.6% | +14.0% | -38.3% | -42.9% | |
| Interest Coverage | 4.54 | 3.88 | 9.07 | 2.55 | 5.33 | 1.39 | 5.93 | 7.10 | 4.91 | 3.65 | 5.28 | 3.02 | 2.74 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying CNMD stock.
CONMED Corporation's current P/E is 25.2x. The average P/E over the last 4 quarters is 46.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CONMED Corporation's current operating margin is 10.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CONMED Corporation's business trajectory between earnings reports.